Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Allogene Therapeutics, Inc. Common Stock

ALLO Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of ALLO by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
ALLO Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
ALLO Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ALLO Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in ALLO holdings by institutional investors

Quarterly net insider trading by ALLO's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Former government officials who have lobbied for ALLO

Quiver Logo

No former government officials on record as having lobbied for ALLO

Revolving Door Dashboard

ALLO Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

ALLO Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
ALLO Income Statement
ALLO Balance Sheet
ALLO Cash Flow
U.S. Patents

New ALLO patent grants

  • Patent Title: Dll3 targeting chimeric antigen receptors and binding agents Apr. 21, 2026
  • Patent Title: Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells Mar. 24, 2026
  • Patent Title: Fasl expression and fasr gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death Mar. 17, 2026
  • Patent Title: Knockdown or knockout of one or more of tap2, nlrc5, b2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products Mar. 17, 2026
  • Patent Title: Chimeric cytokine receptors comprising tgf β binding domains Jan. 20, 2026
  • Patent Title: Method of treatment using anti-cd19 rituximab-resistant chimeric antigen receptors Oct. 21, 2025
  • Patent Title: Protease-activating cd45-gate car Sep. 02, 2025
  • Patent Title: Methods for transducing immune cells Jul. 22, 2025
  • Patent Title: Formulations and processes for car t cell drug products May. 13, 2025
  • Patent Title: Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells Feb. 11, 2025
  • Patent Title: Chimeric antigen receptors with enhanced signaling and activities and uses thereof Feb. 04, 2025
  • Patent Title: Inducible chimeric cytokine receptors Dec. 10, 2024
  • Patent Title: Methods of manufacturing allogeneic car t cells Dec. 10, 2024
  • Patent Title: Modified caspase-9 polypeptides and methods of use thereof Oct. 01, 2024
  • Patent Title: Constitutively active chimeric cytokine receptors Jul. 23, 2024
  • Patent Title: Bcma car-t cells with enhanced activities Jul. 16, 2024
  • Patent Title: Polynucleotides encoding rituximab-resistant chimeric antigen receptors Feb. 13, 2024
  • Patent Title: Chimeric cytokine receptors bearing a pd-1 ectodomain Oct. 17, 2023
  • Patent Title: Anti-talen antibodies and uses thereof Oct. 10, 2023
  • Patent Title: Antibodies against 4g7-derived chimeric antigen receptors Aug. 22, 2023
  • Patent Title: Dll3 targeting chimeric antigen receptors and binding agents Jun. 13, 2023
  • Patent Title: Modified caspase-9 polypeptides and methods of use thereof May. 10, 2022
  • Patent Title: Inhibitory chimeric antigen receptors Jul. 27, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to ALLO from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
ALLO News

Recent insights relating to ALLO

CNBC Recommendations

Recent picks made for ALLO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ALLO

ALLO Analyst Ratings

ALLO Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
ALLO Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $ALLO stock a Buy, Sell, or Hold?

  • What is the price target for $ALLO stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

ALLO Top Shareholders
Shareholder
Shares Held
ALLO Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $ALLO stock?

  • Who owns the most shares of $ALLO stock?

  • What funds own $ALLO stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ALLO Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ALLO Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About ALLO

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

  • Address South San Francisco, CA
  • Market Cap 570.1 million
  • Employees 152
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Allogene Therapeutics, Inc. Common Stock (ALLO) Historical Stock Prices

Allogene Therapeutics, Inc. Common Stock (ALLO) closed at $1.65 on September 25, 2026. Over the past year its adjusted close ranged from $1.05 to $3.06. Daily prices go back to October 11, 2018, 1,999 trading days in all.

  • 1 month-19.12%
  • 3 months-22.54%
  • Year to date+20.44%
  • 1 year+37.50%
  • 3 years-50.89%
  • 5 years-93.57%
  • Max-93.40%
See every congressional and insider trade on the ALLO price chart

Quiver Premium charts ALLO's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 25, 2026 1.69 1.70 1.63 1.65 1.65 3,622,349
Sep 24, 2026 1.67 1.72 1.60 1.67 1.67 7,791,092
Sep 23, 2026 1.73 1.74 1.65 1.67 1.67 5,965,945
Sep 22, 2026 1.72 1.74 1.68 1.71 1.71 5,237,474
Sep 21, 2026 1.71 1.72 1.65 1.69 1.69 5,992,401
Sep 18, 2026 1.73 1.74 1.67 1.69 1.69 12,716,961
Sep 17, 2026 1.74 1.76 1.70 1.73 1.73 3,948,057
Sep 16, 2026 1.74 1.77 1.66 1.69 1.69 5,648,084
Sep 15, 2026 1.80 1.80 1.71 1.72 1.72 3,138,618
Sep 14, 2026 1.77 1.84 1.76 1.78 1.78 7,750,773
Sep 11, 2026 1.80 1.80 1.75 1.78 1.78 3,894,350
Sep 10, 2026 1.73 1.78 1.70 1.76 1.76 5,401,051
Sep 9, 2026 1.85 1.88 1.72 1.73 1.73 7,284,015
Sep 8, 2026 1.93 1.94 1.85 1.86 1.86 7,434,268
Sep 4, 2026 1.97 2.01 1.95 1.97 1.97 4,428,567
Sep 3, 2026 2.00 2.01 1.92 1.98 1.98 4,425,096
Sep 2, 2026 1.97 2.04 1.91 1.98 1.98 5,393,709
Sep 1, 2026 1.96 2.00 1.93 1.99 1.99 4,037,910
Aug 31, 2026 2.01 2.02 1.96 2.00 2.00 4,376,900
Aug 28, 2026 2.08 2.09 2.00 2.02 2.02 3,824,689
Aug 27, 2026 2.04 2.14 2.00 2.09 2.09 4,982,882
Aug 26, 2026 2.17 2.18 2.03 2.04 2.04 5,020,715
Aug 25, 2026 2.05 2.21 2.05 2.17 2.17 6,156,769
Aug 24, 2026 2.11 2.11 2.00 2.03 2.03 4,755,951
Aug 21, 2026 2.12 2.15 2.06 2.09 2.09 4,372,792
Aug 20, 2026 2.19 2.21 2.07 2.10 2.10 4,861,236
Aug 19, 2026 2.08 2.23 2.08 2.23 2.23 6,714,917
Aug 18, 2026 2.07 2.08 2.00 2.03 2.03 4,088,803
Aug 17, 2026 2.05 2.10 2.02 2.08 2.08 4,676,700
Aug 14, 2026 1.96 2.08 1.92 2.05 2.05 4,605,146
Aug 13, 2026 2.13 2.16 1.96 1.98 1.98 6,335,870
Aug 12, 2026 2.13 2.15 2.04 2.07 2.07 4,577,716
Aug 11, 2026 2.11 2.19 2.06 2.12 2.12 4,967,298
Aug 10, 2026 1.99 2.10 1.98 2.10 2.10 5,360,498
Aug 7, 2026 1.98 2.02 1.96 2.01 2.01 3,699,201
Aug 6, 2026 1.95 1.99 1.92 1.97 1.97 3,170,439
Aug 5, 2026 1.90 1.98 1.90 1.95 1.95 5,056,052
Aug 4, 2026 1.87 1.91 1.82 1.90 1.90 4,997,390
Aug 3, 2026 1.87 1.90 1.81 1.84 1.84 7,039,922
Jul 31, 2026 1.97 2.00 1.86 1.88 1.88 5,521,843
Jul 30, 2026 1.86 2.00 1.85 1.97 1.97 10,523,182
Jul 29, 2026 1.72 1.88 1.65 1.81 1.81 12,515,086
Jul 28, 2026 1.75 1.76 1.61 1.66 1.66 9,960,229
Jul 27, 2026 1.80 1.91 1.75 1.75 1.75 6,901,348
Jul 24, 2026 1.83 1.84 1.74 1.74 1.74 4,874,170
Jul 23, 2026 1.82 1.85 1.78 1.82 1.82 5,640,284
Jul 22, 2026 1.84 1.88 1.82 1.86 1.86 4,135,068
Jul 21, 2026 1.76 1.85 1.76 1.85 1.85 4,490,116
Jul 20, 2026 1.80 1.85 1.77 1.77 1.77 3,467,683
Jul 17, 2026 1.75 1.83 1.74 1.79 1.79 4,939,744
Jul 16, 2026 1.88 1.89 1.75 1.79 1.79 6,300,098
Jul 15, 2026 1.87 1.94 1.80 1.90 1.90 6,039,901
Jul 14, 2026 1.94 1.94 1.84 1.85 1.85 5,422,350
Jul 13, 2026 1.97 1.97 1.88 1.93 1.93 8,941,923
Jul 10, 2026 2.10 2.10 1.94 2.00 2.00 7,779,892
Jul 9, 2026 2.13 2.15 2.06 2.10 2.10 6,544,217
Jul 8, 2026 2.11 2.15 2.03 2.12 2.12 12,427,645
Jul 7, 2026 2.10 2.19 1.97 2.15 2.15 14,393,128
Jul 6, 2026 2.08 2.16 2.07 2.09 2.09 10,911,873
Jul 2, 2026 2.13 2.18 2.03 2.08 2.08 9,136,319
Jul 1, 2026 2.05 2.18 2.05 2.11 2.11 12,919,981
Jun 30, 2026 2.24 2.25 2.05 2.08 2.08 17,982,796
Jun 29, 2026 2.15 2.24 2.13 2.22 2.22 14,663,951
Jun 26, 2026 2.02 2.19 2.02 2.13 2.13 25,919,246
Jun 25, 2026 2.05 2.15 2.04 2.06 2.06 9,354,159
Jun 24, 2026 2.08 2.12 2.04 2.05 2.05 9,550,777
Jun 23, 2026 2.03 2.17 2.03 2.07 2.07 4,811,703
Jun 22, 2026 2.03 2.17 2.01 2.10 2.10 6,573,187
Jun 18, 2026 2.02 2.08 1.97 2.00 2.00 23,548,239
Jun 17, 2026 1.90 2.06 1.90 1.96 1.96 6,362,245
Jun 16, 2026 1.95 1.97 1.90 1.90 1.90 5,045,927
Jun 15, 2026 1.93 2.10 1.93 1.94 1.94 5,800,150
Jun 12, 2026 1.88 1.94 1.86 1.90 1.90 8,642,431
Jun 11, 2026 1.76 1.89 1.75 1.88 1.88 6,102,343
Jun 10, 2026 1.79 1.86 1.76 1.78 1.78 7,943,853
Jun 9, 2026 1.88 1.90 1.75 1.82 1.82 7,723,891
Jun 8, 2026 1.91 1.91 1.75 1.85 1.85 9,264,181
Jun 5, 2026 2.01 2.02 1.87 1.88 1.88 7,989,079
Jun 4, 2026 2.02 2.11 2.00 2.04 2.04 7,340,789
Jun 3, 2026 2.07 2.07 1.96 2.00 2.00 9,058,858
Jun 2, 2026 2.16 2.16 2.04 2.05 2.05 7,373,806
Jun 1, 2026 2.18 2.26 2.12 2.15 2.15 8,548,525
May 29, 2026 2.16 2.20 2.04 2.17 2.17 10,289,549
May 28, 2026 2.21 2.28 2.19 2.25 2.25 6,515,390
May 27, 2026 2.16 2.32 2.16 2.25 2.25 10,690,278
May 26, 2026 2.03 2.13 2.02 2.12 2.12 4,770,340
May 22, 2026 1.96 2.05 1.96 2.00 2.00 4,127,266
May 21, 2026 1.88 1.97 1.84 1.96 1.96 4,333,895
May 20, 2026 1.92 1.95 1.86 1.90 1.90 5,201,370
May 19, 2026 1.94 1.99 1.85 1.89 1.89 7,155,270
May 18, 2026 2.03 2.06 1.90 1.94 1.94 6,373,759
May 15, 2026 2.12 2.19 1.97 2.00 2.00 7,668,856
May 14, 2026 2.30 2.35 2.10 2.14 2.14 9,164,513
May 13, 2026 2.31 2.35 2.22 2.33 2.33 6,459,239
May 12, 2026 2.29 2.39 2.27 2.30 2.30 10,034,074
May 11, 2026 2.29 2.39 2.27 2.28 2.28 4,503,825
May 8, 2026 2.29 2.36 2.25 2.28 2.28 4,476,509
May 7, 2026 2.32 2.35 2.25 2.27 2.27 5,680,658
May 6, 2026 2.24 2.36 2.22 2.31 2.31 7,352,979
May 5, 2026 2.29 2.33 2.14 2.17 2.17 5,831,796
May 4, 2026 2.14 2.27 2.12 2.26 2.26 7,509,549
May 1, 2026 2.09 2.17 2.08 2.15 2.15 4,520,799
Apr 30, 2026 2.13 2.17 2.10 2.13 2.13 5,045,224
Apr 29, 2026 2.18 2.22 2.09 2.11 2.11 6,518,228
Apr 28, 2026 2.26 2.29 2.18 2.19 2.19 6,250,695
Apr 27, 2026 2.30 2.39 2.23 2.25 2.25 6,541,961
Apr 24, 2026 2.33 2.38 2.26 2.31 2.31 5,527,351
Apr 23, 2026 2.38 2.41 2.27 2.35 2.35 9,378,939
Apr 22, 2026 2.35 2.50 2.31 2.39 2.39 9,426,378
Apr 21, 2026 2.42 2.43 2.23 2.32 2.32 8,830,340
Apr 20, 2026 2.37 2.56 2.35 2.42 2.42 12,063,719
Apr 17, 2026 2.40 2.53 2.34 2.39 2.39 11,548,755
Apr 16, 2026 2.23 2.50 2.21 2.37 2.37 28,838,768
Apr 15, 2026 1.90 2.17 1.85 2.17 2.17 74,135,391
Apr 14, 2026 3.03 3.08 2.24 2.28 2.28 42,325,123
Apr 13, 2026 4.09 4.46 3.01 3.06 3.06 87,821,040
Apr 10, 2026 2.95 2.95 2.61 2.72 2.72 8,400,344
Apr 9, 2026 2.72 2.91 2.69 2.91 2.91 4,811,512
Apr 8, 2026 2.75 2.82 2.58 2.70 2.70 3,578,070
Apr 7, 2026 2.60 2.63 2.48 2.62 2.62 3,897,843
Apr 6, 2026 2.48 2.71 2.48 2.60 2.60 3,277,145
Apr 2, 2026 2.48 2.66 2.45 2.48 2.48 4,331,502
Apr 1, 2026 2.50 2.67 2.50 2.56 2.56 5,044,067
Mar 31, 2026 2.26 2.50 2.26 2.44 2.44 3,682,842
Mar 30, 2026 2.24 2.33 2.20 2.22 2.22 4,555,889
Mar 27, 2026 2.39 2.50 2.25 2.26 2.26 6,330,340
Mar 26, 2026 2.28 2.50 2.21 2.41 2.41 5,254,940
Mar 25, 2026 2.27 2.37 2.26 2.33 2.33 4,402,947
Mar 24, 2026 2.38 2.43 2.11 2.21 2.21 4,422,339
Mar 23, 2026 2.14 2.60 2.13 2.44 2.44 11,688,884
Mar 20, 2026 2.23 2.26 2.06 2.07 2.07 20,747,775
Mar 19, 2026 2.10 2.27 2.09 2.22 2.22 3,367,934
Mar 18, 2026 2.27 2.29 2.10 2.15 2.15 5,536,403
Mar 17, 2026 2.45 2.46 2.25 2.27 2.27 4,999,392
Mar 16, 2026 2.40 2.54 2.35 2.44 2.44 5,644,012
Mar 13, 2026 2.56 2.73 2.36 2.40 2.40 5,032,911
Mar 12, 2026 2.56 2.58 2.41 2.47 2.47 3,275,333
Mar 11, 2026 2.68 2.73 2.61 2.63 2.63 2,940,881
Mar 10, 2026 2.52 2.71 2.52 2.71 2.71 4,590,630
Mar 9, 2026 2.22 2.52 2.21 2.50 2.50 5,604,658
Mar 6, 2026 2.24 2.31 2.20 2.30 2.30 4,127,463
Mar 5, 2026 2.48 2.50 2.29 2.31 2.31 4,710,399
Mar 4, 2026 2.55 2.60 2.48 2.53 2.53 2,689,533
Mar 3, 2026 2.56 2.63 2.50 2.53 2.53 2,801,354
Mar 2, 2026 2.63 2.73 2.54 2.65 2.65 3,807,697
Feb 27, 2026 2.71 2.80 2.46 2.78 2.78 8,353,125
Feb 26, 2026 2.55 2.74 2.52 2.73 2.73 7,334,091
Feb 25, 2026 2.33 2.56 2.33 2.53 2.53 8,504,574
Feb 24, 2026 2.10 2.31 2.10 2.29 2.29 6,636,211
Feb 23, 2026 2.06 2.15 2.01 2.08 2.08 4,401,146
Feb 20, 2026 2.13 2.13 2.03 2.05 2.05 4,097,490
Feb 19, 2026 2.25 2.30 2.06 2.13 2.13 5,880,539
Feb 18, 2026 2.16 2.28 2.10 2.27 2.27 6,031,247
Feb 17, 2026 1.80 2.17 1.79 2.16 2.16 8,545,483
Feb 13, 2026 1.63 1.83 1.63 1.80 1.80 4,708,840
Feb 12, 2026 1.65 1.67 1.56 1.62 1.62 3,532,190
Feb 11, 2026 1.70 1.71 1.61 1.65 1.65 3,006,341
Feb 10, 2026 1.69 1.84 1.68 1.69 1.69 5,413,505
Feb 9, 2026 1.68 1.71 1.61 1.69 1.69 3,533,204
Feb 6, 2026 1.66 1.75 1.63 1.69 1.69 3,960,804
Feb 5, 2026 1.80 1.82 1.62 1.63 1.63 4,067,441
Feb 4, 2026 1.75 1.85 1.73 1.80 1.80 6,071,929
Feb 3, 2026 1.90 1.97 1.71 1.74 1.74 8,029,803
Feb 2, 2026 1.81 1.93 1.71 1.87 1.87 11,402,120
Jan 30, 2026 1.59 1.89 1.54 1.84 1.84 16,758,196
Jan 29, 2026 1.46 1.59 1.45 1.59 1.59 7,382,874
Jan 28, 2026 1.54 1.54 1.45 1.45 1.45 6,789,836
Jan 27, 2026 1.51 1.62 1.49 1.53 1.53 6,543,956
Jan 26, 2026 1.71 1.72 1.46 1.51 1.51 8,188,522
Jan 23, 2026 1.73 1.83 1.70 1.72 1.72 7,538,591
Jan 22, 2026 1.63 1.75 1.61 1.72 1.72 5,943,311
Jan 21, 2026 1.57 1.63 1.55 1.60 1.60 4,294,663
Jan 20, 2026 1.61 1.62 1.53 1.57 1.57 4,831,503
Jan 16, 2026 1.64 1.67 1.59 1.63 1.63 4,731,819
Jan 15, 2026 1.70 1.72 1.60 1.61 1.61 5,638,948
Jan 14, 2026 1.64 1.72 1.63 1.70 1.70 4,631,482
Jan 13, 2026 1.72 1.74 1.62 1.64 1.64 4,992,684
Jan 12, 2026 1.84 1.84 1.65 1.67 1.67 8,559,967
Jan 9, 2026 1.66 1.88 1.66 1.71 1.71 12,310,493
Jan 8, 2026 1.50 1.54 1.46 1.49 1.49 3,090,928
Jan 7, 2026 1.45 1.54 1.43 1.49 1.49 4,254,453
Jan 6, 2026 1.35 1.48 1.34 1.41 1.41 5,210,270
Jan 5, 2026 1.35 1.38 1.31 1.35 1.35 2,422,704
Jan 2, 2026 1.38 1.39 1.31 1.35 1.35 2,315,461
Dec 31, 2025 1.31 1.38 1.30 1.37 1.37 3,054,747
Dec 30, 2025 1.38 1.38 1.29 1.31 1.31 3,750,818
Dec 29, 2025 1.37 1.41 1.34 1.38 1.38 1,830,744
Dec 26, 2025 1.41 1.42 1.36 1.38 1.38 2,197,378
Dec 24, 2025 1.37 1.42 1.35 1.40 1.40 1,051,498
Dec 23, 2025 1.45 1.46 1.32 1.36 1.36 4,598,871
Dec 22, 2025 1.42 1.52 1.38 1.47 1.47 2,442,488
Dec 19, 2025 1.42 1.48 1.40 1.42 1.42 5,715,237
Dec 18, 2025 1.43 1.46 1.38 1.42 1.42 2,345,091
Dec 17, 2025 1.54 1.56 1.41 1.42 1.42 1,906,339
Dec 16, 2025 1.51 1.56 1.44 1.54 1.54 2,523,321
Dec 15, 2025 1.51 1.51 1.43 1.47 1.47 2,021,451
Dec 12, 2025 1.56 1.56 1.50 1.51 1.51 2,277,741
Dec 11, 2025 1.46 1.56 1.45 1.55 1.55 2,881,931
Dec 10, 2025 1.42 1.50 1.41 1.48 1.48 2,234,610
Dec 9, 2025 1.43 1.52 1.42 1.42 1.42 3,816,995
Dec 8, 2025 1.45 1.46 1.39 1.45 1.45 1,623,169
Dec 5, 2025 1.46 1.47 1.42 1.43 1.43 2,435,519
Dec 4, 2025 1.48 1.51 1.41 1.44 1.44 1,541,249
Dec 3, 2025 1.35 1.52 1.33 1.52 1.52 3,429,231
Dec 2, 2025 1.33 1.38 1.30 1.34 1.34 2,216,140
Dec 1, 2025 1.44 1.45 1.34 1.37 1.37 1,951,212
Nov 28, 2025 1.42 1.49 1.41 1.46 1.46 1,405,592
Nov 26, 2025 1.36 1.43 1.31 1.42 1.42 2,766,631
Nov 25, 2025 1.34 1.40 1.30 1.36 1.36 2,502,693
Nov 24, 2025 1.23 1.35 1.22 1.35 1.35 3,837,128
Nov 21, 2025 1.22 1.25 1.20 1.23 1.23 1,589,154
Nov 20, 2025 1.28 1.33 1.22 1.24 1.24 2,614,614
Nov 19, 2025 1.27 1.35 1.23 1.26 1.26 2,215,641
Nov 18, 2025 1.23 1.31 1.22 1.31 1.31 2,837,146
Nov 17, 2025 1.22 1.28 1.21 1.23 1.23 2,369,849
Nov 14, 2025 1.17 1.25 1.16 1.23 1.23 2,647,952
Nov 13, 2025 1.21 1.24 1.19 1.20 1.20 1,762,427
Nov 12, 2025 1.26 1.27 1.21 1.23 1.23 2,429,101
Nov 11, 2025 1.16 1.27 1.15 1.24 1.24 2,280,789
Nov 10, 2025 1.23 1.23 1.16 1.18 1.18 2,480,517
Nov 7, 2025 1.05 1.18 1.04 1.18 1.18 3,138,038
Nov 6, 2025 1.10 1.10 1.05 1.05 1.05 2,716,285
Nov 5, 2025 1.14 1.14 1.08 1.11 1.11 1,765,635
Nov 4, 2025 1.16 1.18 1.05 1.11 1.11 2,138,503
Nov 3, 2025 1.25 1.26 1.17 1.18 1.18 2,098,226
Oct 31, 2025 1.25 1.28 1.21 1.24 1.24 1,645,235
Oct 30, 2025 1.21 1.26 1.21 1.21 1.21 1,243,587
Oct 29, 2025 1.26 1.28 1.21 1.22 1.22 2,921,133
Oct 28, 2025 1.24 1.31 1.21 1.26 1.26 3,621,926
Oct 27, 2025 1.21 1.26 1.21 1.23 1.23 2,152,186
Oct 24, 2025 1.21 1.24 1.20 1.20 1.20 1,739,937
Oct 23, 2025 1.20 1.23 1.19 1.21 1.21 1,647,653
Oct 22, 2025 1.27 1.27 1.19 1.21 1.21 2,963,369
Oct 21, 2025 1.29 1.32 1.23 1.26 1.26 2,317,171
Oct 20, 2025 1.26 1.33 1.25 1.29 1.29 3,782,938
Oct 17, 2025 1.25 1.27 1.21 1.23 1.23 2,556,266
Oct 16, 2025 1.27 1.38 1.25 1.27 1.27 3,317,352
Oct 15, 2025 1.24 1.30 1.23 1.27 1.27 2,903,924
Oct 14, 2025 1.23 1.26 1.20 1.23 1.23 2,820,617
Oct 13, 2025 1.32 1.33 1.20 1.27 1.27 3,785,980
Oct 10, 2025 1.44 1.46 1.20 1.23 1.23 7,230,957
Oct 9, 2025 1.48 1.53 1.45 1.51 1.51 3,065,079
Oct 8, 2025 1.36 1.48 1.35 1.47 1.47 3,574,539
Oct 7, 2025 1.39 1.41 1.29 1.35 1.35 2,416,386
Oct 6, 2025 1.40 1.43 1.36 1.38 1.38 2,235,633
Oct 3, 2025 1.27 1.34 1.27 1.33 1.33 2,435,925
Oct 2, 2025 1.25 1.29 1.23 1.29 1.29 2,488,522
Oct 1, 2025 1.24 1.27 1.23 1.24 1.24 2,403,216
Sep 30, 2025 1.27 1.31 1.20 1.24 1.24 2,700,230
Sep 29, 2025 1.26 1.30 1.21 1.27 1.27 4,928,557
Sep 26, 2025 1.21 1.26 1.19 1.25 1.25 3,271,771
Sep 25, 2025 1.21 1.22 1.18 1.20 1.20 2,214,675

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Allogene Therapeutics, Inc. Common Stock Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at ALLO, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation